Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Iepsen, EW, Lundgren, JR, Hartmann, B, Pedersen, O, Hansen, T, Jørgensen, NR, Jensen, J-EB, Holst, JJ, Madsbad, S & Torekov, SS 2015, 'GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women' The Journal of clinical endocrinology and metabolism, bind 100, nr. 8, s. 2909-17. https://doi.org/10.1210/jc.2015-1176

APA

CBE

MLA

Vancouver

Author

Iepsen, Eva W ; Lundgren, Julie R ; Hartmann, Bolette ; Pedersen, Oluf ; Hansen, Torben ; Jørgensen, Niklas R ; Jensen, Jens-Erik B ; Holst, Jens J ; Madsbad, Sten ; Torekov, Signe S. / GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women. I: The Journal of clinical endocrinology and metabolism. 2015 ; Bind 100, Nr. 8. s. 2909-17.

Bibtex

@article{12255979d5c84ce495bd675f99e665eb,
title = "GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women",
abstract = "CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction.DESIGN: Randomized control study.SETTING: Outpatient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.INTERVENTION: After a low-calorie-diet-induced 12{\%} weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95{\%} confidence interval, 5-48; P = .01), although the 12{\%} weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16{\%} (7 ± 3 μg/L) vs a 2{\%} (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16{\%} and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.",
author = "Iepsen, {Eva W} and Lundgren, {Julie R} and Bolette Hartmann and Oluf Pedersen and Torben Hansen and J{\o}rgensen, {Niklas R} and Jensen, {Jens-Erik B} and Holst, {Jens J} and Sten Madsbad and Torekov, {Signe S}",
year = "2015",
month = "8",
doi = "10.1210/jc.2015-1176",
language = "English",
volume = "100",
pages = "2909--17",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The/Endocrine Society",
number = "8",

}

RIS

TY - JOUR

T1 - GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women

AU - Iepsen, Eva W

AU - Lundgren, Julie R

AU - Hartmann, Bolette

AU - Pedersen, Oluf

AU - Hansen, Torben

AU - Jørgensen, Niklas R

AU - Jensen, Jens-Erik B

AU - Holst, Jens J

AU - Madsbad, Sten

AU - Torekov, Signe S

PY - 2015/8

Y1 - 2015/8

N2 - CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction.DESIGN: Randomized control study.SETTING: Outpatient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.

AB - CONTEXT: Recent studies indicate that glucagon-like peptide (GLP)-1 regulates bone turnover, but the effects of GLP-1 receptor agonists (GLP-1 RAs) on bone in obese weight-reduced individuals are unknown.OBJECTIVE: To investigate the role of GLP-1 RAs on bone formation and weight loss-induced bone mass reduction.DESIGN: Randomized control study.SETTING: Outpatient research hospital clinic.PARTICIPANTS: Thirty-seven healthy obese women with body mass index of 34 ± 0.5 kg/m(2) and age 46 ± 2 years.INTERVENTION: After a low-calorie-diet-induced 12% weight loss, participants were randomized to treatment with or without administration of the GLP-1 RA liraglutide (1.2 mg/d) for 52 weeks. In case of weight gain, up to two meals per day could be replaced with a low-calorie-diet product to maintain the weight loss.MAIN OUTCOME MEASURES: Total, pelvic, and arm-leg bone mineral content (BMC) and bone markers [C-terminal telopeptide of type 1 collagen (CTX-1) and N-terminal propeptide of type 1 procollagen (P1NP)] were investigated before and after weight loss and after 52-week weight maintenance. Primary endpoints were changes in BMC and bone markers after 52-week weight maintenance with or without GLP-1 RA treatment.RESULTS: Total, pelvic, and arm-leg BMC decreased during weight maintenance in the control group (P < .0001), but not significantly in the liraglutide group. Thus, total and arm-leg BMC loss was four times greater in the control group compared to the liraglutide group (estimated difference, 27 g; 95% confidence interval, 5-48; P = .01), although the 12% weight loss was maintained in both groups. In the liraglutide group, the bone formation marker P1NP increased by 16% (7 ± 3 μg/L) vs a 2% (-1 ± 4 μg/L) decrease in the control group (P < .05). The bone resorption marker CTX-1 collagen did not change during the weight loss maintenance phase.CONCLUSIONS: Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low-calorie diet, supporting its role as a safe weight-lowering agent.

U2 - 10.1210/jc.2015-1176

DO - 10.1210/jc.2015-1176

M3 - Journal article

VL - 100

SP - 2909

EP - 2917

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -

ID: 45570349